Epcoritamab for first relapse of large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have large B-cell lymphoma (like DLBCL) that came back after or didn't fully respond to your first treatment.
- You should have had only one prior cancer treatment (your first one), and that treatment must have included drugs like rituximab and CHOP chemotherapy.
- You need to be 18 or older, with a PET scan showing active disease, and be in fairly good health (ECOG score 0-2).
- You must not be a candidate for CAR-T therapy or have chosen not to get it, and you cannot have had a stem cell transplant before.
- Your kidneys, liver, and heart must work well enough (specific blood test and heart scan results are needed), and you cannot have lymphoma in your brain or spinal cord.
- You must agree to use effective birth control if you or your partner could become pregnant, and avoid blood or tissue donation during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.